Biological markers for longevity and diseases and uses thereof
View Patent ↗This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the -641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease.
1. A method of determining a subject's likelihood of longevity, likelihood of developing a cardiovascular related disease, likelihood of developing a metabolic syndrome, or likelihood of retaining cognitive function during aging, wherein the cardiovascular related disease is selected from the group consisting of hypertension, diabetes mellitus, myocardial infarction, stroke and transient ischemic attack,
the method comprising comparing high density lipoprotein (HDL) particle size from the subject's plasma with high density lipoprotein (HDL) particle size from a control population,
wherein an average size of the subject's high density lipoprotein (HDL) particles that is statistically significantly larger than an average size of high density lipoprotein (HDL) particles from the control population indicates that the subject has an increased likelihood of longevity, a decreased likelihood of developing a cardiovascular related disease, a decreased likelihood of developing a metabolic syndrome or an increased likelihood of retaining cognitive function during aging, or
wherein an average size of the subject's high density lipoprotein (HDL) particles that is statistically significantly smaller than an average size of high density lipoprotein (HDL) particles from the control population indicates that the subject has an increased likelihood of developing a cardiovascular related disease or an increased likelihood of developing a metabolic syndrome.
2. The method of claim 1 , which comprises determining a subject's likelihood of longevity.
3. The method of claim 1 , which comprises determining a subject's likelihood of developing a cardiovascular related disease.
4. The method of claim 1 , which comprises determining a subject's likelihood of developing a metabolic syndrome.
5. The method of claim 1 , which comprises determining a subject's likelihood of retaining cognitive function during aging.
6. The method of claim 1 , which further comprises comparing the number of large size HDL particles as a percentage of total HDL particles from the subject with the percentage of large size HDL particles from the control population, wherein large size HDL particles have a diameter of 8.8-13 nm, and
wherein a statistically significant greater number of large size HDL particles as a percentage of total HDL particles from the subject than from the control population indicates that the subject has an increased likelihood of longevity, a decreased likelihood of developing a cardiovascular related disease, a decreased likelihood of developing a metabolic syndrome or an increased likelihood of retaining cognitive function during aging, or
wherein a statistically significant smaller number of large size HDL particles as a percentage of total HDL particles from the subject than from the control population indicates that the subject has an increased likelihood of developing a cardiovascular related disease or an increased likelihood of developing a metabolic syndrome.
7. The method of claim 1 , which further comprises comparing the number of medium size HDL particles as a percentage of total HDL particles from the subject with the percentage of medium size HDL particles from the control population, wherein medium size HDL particles have a diameter of 8.2-8.8 nm and wherein a statistically significant smaller number of medium size HDL particles as a percentage of total HDL particles from the subject than from the control population indicates that the subject has an increased likelihood of longevity.
8. The method of claim 1 , wherein the subject's high density lipoprotein (HDL) particles have an average size that is at least 2% greater than that of high density lipoprotein (HDL) particle average size from the control population.
9. The method of claim 1 , wherein the subject's high density lipoprotein (HDL) particles have an average size that is at least 2% smaller than that of high density lipoprotein (HDL) particle average size from the control population.
10. The method of claim 1 , wherein the subject's high density lipoprotein (HDL) particles have an average size that is at least 0.2 nm larger in diameter than that of high density lipoprotein (HDL) particle average size from the control population.
11. The method of claim 1 , wherein the subject and the control population are the same gender.